Delayed
Swiss Exchange
10:06:39 01/03/2023 pm IST
|
5-day change
|
1st Jan Change
|
500
CHF
|
+194.12%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,83,911
|
4,14,310
|
4,50,358
|
4,61,849
|
3,77,317
|
3,55,707
|
-
|
-
|
Enterprise Value (EV)
1 |
3,92,320
|
4,24,391
|
4,52,501
|
4,77,989
|
3,83,722
|
3,49,523
|
3,36,690
|
3,24,327
|
P/E ratio
|
25.9
x
|
28.6
x
|
21.9
x
|
26.2
x
|
11.4
x
|
17.1
x
|
15.5
x
|
14.6
x
|
Yield
|
2.57%
|
2.53%
|
2.45%
|
2.52%
|
3%
|
3.26%
|
3.41%
|
3.56%
|
Capitalization / Revenue
|
4.68
x
|
5.02
x
|
4.8
x
|
4.86
x
|
4.43
x
|
4.02
x
|
3.91
x
|
3.78
x
|
EV / Revenue
|
4.78
x
|
5.14
x
|
4.83
x
|
5.03
x
|
4.51
x
|
3.95
x
|
3.7
x
|
3.45
x
|
EV / EBITDA
|
14
x
|
15.6
x
|
12.4
x
|
14.6
x
|
12.6
x
|
10.9
x
|
10.2
x
|
9.36
x
|
EV / FCF
|
19.7
x
|
21
x
|
22.9
x
|
27.8
x
|
21
x
|
15
x
|
14.8
x
|
13.8
x
|
FCF Yield
|
5.08%
|
4.76%
|
4.37%
|
3.6%
|
4.76%
|
6.66%
|
6.76%
|
7.27%
|
Price to Book
|
6.46
x
|
9.53
x
|
6.08
x
|
6.13
x
|
5.84
x
|
4.69
x
|
4.24
x
|
3.83
x
|
Nbr of stocks (in thousands)
|
26,31,872
|
26,32,543
|
26,32,597
|
26,14,484
|
24,07,279
|
24,06,679
|
-
|
-
|
Reference price
2 |
145.9
|
157.4
|
171.1
|
176.6
|
156.7
|
147.8
|
147.8
|
147.8
|
Announcement Date
|
22/01/20
|
26/01/21
|
25/01/22
|
24/01/23
|
23/01/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
82,059
|
82,584
|
93,775
|
94,943
|
85,159
|
88,404
|
90,926
|
94,081
|
EBITDA
1 |
27,979
|
27,145
|
36,634
|
32,630
|
30,414
|
32,205
|
33,044
|
34,640
|
EBIT
1 |
25,593
|
24,574
|
29,244
|
29,965
|
27,460
|
28,997
|
29,934
|
31,186
|
Operating Margin
|
31.19%
|
29.76%
|
31.19%
|
31.56%
|
32.25%
|
32.8%
|
32.92%
|
33.15%
|
Earnings before Tax (EBT)
1 |
17,328
|
16,497
|
22,776
|
21,725
|
15,062
|
24,583
|
24,124
|
23,922
|
Net income
1 |
15,119
|
14,714
|
20,878
|
17,941
|
35,153
|
21,069
|
23,092
|
24,466
|
Net margin
|
18.42%
|
17.82%
|
22.26%
|
18.9%
|
41.28%
|
23.83%
|
25.4%
|
26.01%
|
EPS
2 |
5.630
|
5.510
|
7.810
|
6.730
|
13.72
|
8.626
|
9.523
|
10.13
|
Free Cash Flow
1 |
19,918
|
20,189
|
19,758
|
17,185
|
18,248
|
23,276
|
22,758
|
23,581
|
FCF margin
|
24.27%
|
24.45%
|
21.07%
|
18.1%
|
21.43%
|
26.33%
|
25.03%
|
25.06%
|
FCF Conversion (EBITDA)
|
71.19%
|
74.37%
|
53.93%
|
52.67%
|
60%
|
72.27%
|
68.87%
|
68.07%
|
FCF Conversion (Net income)
|
131.74%
|
137.21%
|
94.64%
|
95.79%
|
51.91%
|
110.47%
|
98.55%
|
96.38%
|
Dividend per Share
2 |
3.750
|
3.980
|
4.190
|
4.450
|
4.700
|
4.824
|
5.038
|
5.266
|
Announcement Date
|
22/01/20
|
26/01/21
|
25/01/22
|
24/01/23
|
23/01/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
24,804
|
23,426
|
24,020
|
23,791
|
23,706
|
24,746
|
25,530
|
21,351
|
21,395
|
21,383
|
22,312
|
22,249
|
22,443
|
21,981
|
23,081
|
EBITDA
1 |
7,939
|
9,305
|
9,011
|
9,299
|
7,804
|
8,880
|
8,912
|
8,071
|
6,333
|
7,973
|
8,370
|
8,291
|
7,688
|
8,266
|
8,443
|
EBIT
1 |
6,096
|
7,536
|
7,267
|
7,614
|
7,093
|
8,204
|
8,189
|
7,374
|
5,638
|
7,236
|
7,405
|
7,427
|
6,902
|
7,482
|
7,721
|
Operating Margin
|
24.58%
|
32.17%
|
30.25%
|
32%
|
29.92%
|
33.15%
|
32.08%
|
34.54%
|
26.35%
|
33.84%
|
33.19%
|
33.38%
|
30.75%
|
34.04%
|
33.45%
|
Earnings before Tax (EBT)
1 |
4,836
|
5,862
|
5,840
|
5,822
|
4,201
|
-737
|
6,762
|
5,217
|
4,826
|
6,440
|
6,702
|
6,302
|
5,818
|
-
|
-
|
Net income
1 |
4,736
|
-
|
-
|
4,458
|
3,520
|
-68
|
5,144
|
26,028
|
4,049
|
5,354
|
5,446
|
5,200
|
7,348
|
5,471
|
5,794
|
Net margin
|
19.09%
|
-
|
-
|
18.74%
|
14.85%
|
-0.27%
|
20.15%
|
121.91%
|
18.92%
|
25.04%
|
24.41%
|
23.37%
|
32.74%
|
24.89%
|
25.1%
|
EPS
2 |
1.770
|
1.930
|
1.800
|
1.680
|
1.330
|
-0.0300
|
1.960
|
10.21
|
1.670
|
2.200
|
2.202
|
2.212
|
2.710
|
2.294
|
2.391
|
Dividend per Share
2 |
1.060
|
1.060
|
1.130
|
1.130
|
1.130
|
1.130
|
1.190
|
1.190
|
1.190
|
1.190
|
1.225
|
1.205
|
1.225
|
1.221
|
1.221
|
Announcement Date
|
25/01/22
|
19/04/22
|
19/07/22
|
18/10/22
|
24/01/23
|
18/04/23
|
20/07/23
|
17/10/23
|
23/01/24
|
16/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
8,409
|
10,081
|
2,143
|
16,140
|
6,405
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
6,184
|
19,018
|
31,381
|
Leverage (Debt/EBITDA)
|
0.3005
x
|
0.3714
x
|
0.0585
x
|
0.4946
x
|
0.2106
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
19,918
|
20,189
|
19,758
|
17,185
|
18,248
|
23,276
|
22,758
|
23,581
|
ROE (net income / shareholders' equity)
|
39.1%
|
34.9%
|
38.2%
|
23.8%
|
34.9%
|
35.2%
|
33.1%
|
31.5%
|
ROA (Net income/ Total Assets)
|
15%
|
12.9%
|
14.7%
|
9.71%
|
14.3%
|
13.9%
|
14%
|
14.3%
|
Assets
1 |
1,00,753
|
1,14,174
|
1,42,233
|
1,84,698
|
2,45,525
|
1,51,462
|
1,65,151
|
1,71,052
|
Book Value Per Share
2 |
22.60
|
16.50
|
28.20
|
28.80
|
26.90
|
31.50
|
34.80
|
38.60
|
Cash Flow per Share
2 |
8.720
|
8.810
|
8.750
|
7.960
|
8.900
|
11.10
|
11.10
|
13.40
|
Capex
1 |
3,498
|
3,347
|
3,652
|
4,009
|
4,543
|
4,047
|
4,060
|
4,150
|
Capex / Sales
|
4.26%
|
4.05%
|
3.89%
|
4.22%
|
5.33%
|
4.58%
|
4.46%
|
4.41%
|
Announcement Date
|
22/01/20
|
26/01/21
|
25/01/22
|
24/01/23
|
23/01/24
|
-
|
-
|
-
|
Last Close Price
147.8
USD Average target price
171.9
USD Spread / Average Target +16.34% Consensus |
1st Jan change
|
Capi.
|
---|
| +42.83% | 750B | | +34.11% | 606B | | +18.06% | 326B | | +4.63% | 286B | | +17.64% | 246B | | +10.98% | 213B | | -3.27% | 213B | | +2.43% | 167B | | +6.67% | 165B |
Other Pharmaceuticals
|